LNTH - Lantheus Holdings

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Lantheus Non-GAAP EPS of $1.75, revenue of $354M
• Lantheus Q4 2023 Earnings Preview
• Perspective gains as B. Riley sees over 100% upside on radiopharma prospects
• Lantheus appoints CEO
• FDA accepts Lantheus's application for generic Lutathera
• Lantheus says FY23 worldwide revenue is expected to be in the range of $1.295 - 1.297B
• Eli Lilly purchase of Point Bio to close Wednesday after tender offer completed
• William Blair downgrades Lantheus to market perform
• Lantheus, Point BioPharma drop amid results of SPLASH study on prostate cancer
• Eli Lilly surprised as POINT Biopharma acquisition remains incomplete
• Lantheus Non-GAAP EPS of $1.47 beats by $0.15, revenue of $319.9M beats by $5.48M
• Lantheus Q3 2023 Earnings Preview
• POINT Biopharma trades through deal price with Eli Lilly
• Eli Lilly to acquire Point Biopharma in $1.4B deal (update)
• Lantheus to discontinue radiotherapy Azedra
• POINT Biopharma slips after pipeline update
• Lantheus to sell RELISTOR's royalty rights, intensifies focus on radiopharmaceutical business
• Lantheus Non-GAAP EPS of $1.54 beats by $0.23, revenue of $321.7M beats by $15.04M
• Lantheus Q2 2023 Earnings Preview
• Lantheus prostate cancer diagnostics recommended for EU approval